Cytokine therapy is a type of immunotherapy that directly activates the immune system to detect and kill cancer. In this article, we’re answering your questions about cytokine therapy to get you up to speed with the latest advances in this exciting field.

In this article, we’re answering your questions about immunotherapy for cancer, discussing our own cancer immunotherapy research here at Audax Biosciences, and exploring the potential of cancer immunotherapy to transform the lives of patients with cancer.

oNKo-innate has grown from a pioneering NK cell biology startup into a fully integrated biotechnology company with global ambitions. Today, we are proud to introduce our new name: Audax Biosciences.

New Cancer Cell paper: We discovered molecular brakes (UBE2F, ARIH2) that limit NK cell cancer-fighting ability. Targeting these proteins could enhance immunotherapy effectiveness while avoiding toxicity—opening doors to safer, more powerful treatments.

Explores the concept of the cold tumor microenvironment, the difference between a cold tumors and hot tumors, and how immunotherapy can heat up cold tumors.

Dr. House and Dr. Lai, senior scientists in Audax’s immunobiology team, were interviewed on the Synthego CRISPR Cuts podcast about their experiences in academia and biotech, their research in immuno-oncology and the broader impact of CRISPR in cancer research.

oNKo‑innate was honoured as the Australian Emerging Company of the Year at the 2021 AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards following its rapid growth and pioneering work in harnessing the immune system to develop next‑generation immunotherapies.